Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

101.04
2.50 2.40
NYSE
Prev Close 103.56
Open 103.80
Day Low/High 103.66 / 104.22
52 Wk Low/High 62.57 / 151.51
Volume 17.17K
Exchange NYSE
Shares Outstanding 65.50B
Market Cap 7.16B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Traders Should Be Stopped Out of Biohaven Pharmaceutical

Traders Should Be Stopped Out of Biohaven Pharmaceutical

For now I would take a wait and see approach.

Biohaven Pharmaceutical Is Charging Higher

Biohaven Pharmaceutical Is Charging Higher

Here's where it might be headed.

Biohaven Pharmaceutical Is Ready to Climb Higher on the Charts

Biohaven Pharmaceutical Is Ready to Climb Higher on the Charts

Continue to hold previously recommended longs.

Biohaven Pharmaceuticals Looks Ready to Trade Higher

Biohaven Pharmaceuticals Looks Ready to Trade Higher

Let's review the charts and indicators.

Biohaven Pharmaceutical Still Looks Unattractive Based on Its Charts

Biohaven Pharmaceutical Still Looks Unattractive Based on Its Charts

The migraine drugmaker has been sending weak technical signals for a few months now.

Biohaven Pharmaceutical Could Pull Back From Here

Biohaven Pharmaceutical Could Pull Back From Here

Take profits or raise your stop protection.

Taking a Wait and Watch Strategy on Biohaven Pharmaceutical

Taking a Wait and Watch Strategy on Biohaven Pharmaceutical

BHVN has made a relatively big advance since April and a period of consolidation or sideways price action is probably likely at this time.

The Market Is Setting Up for the Next Big Move

The Market Is Setting Up for the Next Big Move

Despite the lackluster action there are some pockets of good stock picking again.

3 Promising Biotech Stocks to Buy on a Market Pullback

3 Promising Biotech Stocks to Buy on a Market Pullback

Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.

What's Making This Market So Difficult Is That It's So Lopsided

What's Making This Market So Difficult Is That It's So Lopsided

Even if you are bullish and want to try to ride the uptrend the entry points are extremely difficult.

Biohaven Pharmaceutical Needs More Bottom Development Before Becoming a Buy

Biohaven Pharmaceutical Needs More Bottom Development Before Becoming a Buy

You can't rush drugs to market and you can't rush a market bottom.

Anatomy of a Lucrative Biotech Trade

Anatomy of a Lucrative Biotech Trade

The trade involves using a buy-write option strategy after negative news knocks down a biotech stock into oversold territory.

It's Extremely Tough to Keep Chasing This Market Higher

It's Extremely Tough to Keep Chasing This Market Higher

Market players have one eye on Fed Chair Jerome Powell who is testifying before Congress.

Trading Notes on 21 Stocks I Currently Own

Trading Notes on 21 Stocks I Currently Own

Here are my takes on stocks in biotech and other companies I own right now.

We Have a Market That Has Become a Little Extended

We Have a Market That Has Become a Little Extended

This looks like a normal pause within an uptrend.

Release Your 'Inner Spock' When Investing in Biotech Stocks

Release Your 'Inner Spock' When Investing in Biotech Stocks

Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.

2 Single Hitters That Could Score With the 'Write' Strategy

2 Single Hitters That Could Score With the 'Write' Strategy

These stocks look ripe for a buy-write options win.

Potential Trades I'm Looking at on the Fed Decision

Potential Trades I'm Looking at on the Fed Decision

A dovish Fed will weaken the dollar, which will weaken gold, and vice versa.